Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
The Source
CNBC
Business
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
CNBC·2h ago·3 min read
US
Ukraine’s Zelenskyy ousts defense minister in surprise shake-up as protest calls emerge
CNBC·4h ago·3 min read
US
U.S. slaps 25% tariff on most Brazilian goods over ‘unfair trade practices’
CNBC·6h ago·3 min read
US
Ex-Fed advisor gets over three years in prison for lying about China ties
CNBC·10h ago·3 min read
Related
On this beat
Health
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
TWSJ·27m ago·3 min read
Health
The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve
TWSJ·1h ago·3 min read
Health
Do you know which countries have the highest longevity? How about the U.S. state where people live the longest, on average? Test your know-how with this WSJ quiz.
TWSJ·2h ago·3 min read
Health
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
CNBC·16h ago·3 min read